Type 1 diabetes mellitus provoked by peginterferon α-2b plus ribavirin treatment for chronic hepatitis C

Internal Medicine

Volumn 47, Issue 8, 2008, Pages 747-749

  Tanaka, Junichirou ^a   Sugimoto, Kazushi ^a   Shiraki, Katsuya ^a   Beppu, Tetsuya ^a   Yoneda, Kentarou ^a   Fuke, Hiroyuki ^a   Yamamoto, Norihiko ^a   Ito, Keiichi ^a   Takei, Yoshiyuki ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Peginterferon 2b; Type 1 diabetes mellitus

Indexed keywords

AUTOANTIBODY; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR MARKER; ALPHA2B INTERFERON; ANTIDIABETIC AGENT; ANTIVIRUS AGENT; GLUTAMATE DECARBOXYLASE; PEGINTERFERON ALFA-2B;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CASE REPORT; DIET RESTRICTION; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIVER FUNCTION TEST; MALE; METABOLIC PARAMETERS; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ANTIVIRAL AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMATE DECARBOXYLASE; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 44649083382     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0653     Document Type: Article

References (11)

1. Fabris P, Floreani A, Tositti G, Vergani D, de Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18: 549-558, 2003.
2. Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A. A case of autoinmume polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol 56: 238-239, 2003.
3. Schories M, Peters T, Rasenack J, Reincke M. Autoantibodies against islet-cell antigens and type 1 diabetes after treatment with interferon-alpha. Dtsch Med Wochenshr 129: 1120-1124, 2004 (in German).
4. Primo Vera J. Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C. Gastroenterol Hepatol 27: 69, 2004 (in Spanish).
5. Jabr Fl. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. Am J Med 115: 158-159, 2003.
6. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta. E, Manghisi OG. Onset of type 1 diabetes mellitus during pegin-terferon α-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 18: 689-692, 2006.
7. Isaacs A, Lindenmann J. Virus interference. I. The interferons. Proc R Soc Lond [Biol] 147: 258-267, 1957.
8. Hoofhagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315: 1575-1578, 1986.
9. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 (3 supp] 1): 112S-121S, 1997.
10. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 340: 548, 1992.
11. Kaufman DL, Eriander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 89: 283-292, 1992.